How to access Zolgensma from Egypt — the named-patient coordination pathway, 2026

By Reserve Meds · Clinical & regulatory team · Last reviewed 2026-04-23

An Egyptian child with biallelic SMN1 mutations and a clinical or pre-symptomatic diagnosis of spinal muscular atrophy (SMA) — typically under two years of age and meeting weight and serology criteria — may be evaluated by their treating paediatric neurologist for Zolgensma (onasemnogene abeparvovec). Zolgensma is FDA-approved, developed by Novartis Gene Therapies, and is a one-time intravenous AAV9-based gene therapy delivering a functional SMN1 gene. Because Zolgensma is a single-dose therapy with a narrow eligibility window, access involves a coordinated pathway rather than a routine prescription.

This guide explains the legal and operational pathway, what your paediatric neurologist needs to coordinate, typical timing and cost bands, and where Reserve Meds fits in.

The clinical situation

Zolgensma is a one-time intravenous infusion of a recombinant AAV9 vector carrying the human SMN1 gene. Key eligibility elements:

• Biallelic SMN1 mutations — confirmed on molecular testing.
• Age — current FDA labelling covers paediatric patients under two years at time of dosing.
• Weight — dosing is weight-based; practical handling becomes rate-limiting for heavier children.
• Anti-AAV9 serology — elevated anti-AAV9 antibody titres exclude eligibility.
• Prior SMA therapy — prior nusinersen or risdiplam is not a contraindication.
• Hepatic and cardiac baseline — required; peri-infusion corticosteroids mitigate transaminitis risk.

Administration is at a gene-therapy-qualified paediatric centre. Egypt's tertiary paediatric neurology infrastructure is developing its gene-therapy capability; depending on the administering-centre option your neurologist selects, the infusion may be delivered in Egypt or via cross-border referral.

Is Zolgensma legally accessible for Egyptian patients?

Yes — via the Egyptian Drug Authority (EDA) named-patient / personal-use import framework. The EDA permits a treating physician at a qualified paediatric centre to import a medicine not yet locally registered when (a) the medicine is approved by a recognised reference authority such as the US FDA, (b) no clinically equivalent alternative is routinely available, (c) the physician accepts clinical responsibility, and (d) chain of custody through a licensed importer is documented.

For Zolgensma specifically, the application emphasises the administering centre's gene-therapy capability and the ultra-cold-chain handling requirements. Where the administering centre is outside Egypt, the EDA medical-referral framework supports cross-border care coordination.

How the pathway works, step by step

1. Consultation with your paediatric neurologist. SMN1 confirmation, age/weight eligibility, anti-AAV9 serology, hepatic and cardiac baseline, clinical rationale letter.
2. Administering-centre identification. A gene-therapy-qualified paediatric centre is nominated — in Egypt where infrastructure is in place, or via cross-border referral otherwise.
3. EDA named-patient application. Your physician files the dossier including rationale, patient reference, centre capability attestation, and single-dose plan.
4. US-side sourcing. Reserve Meds coordinates with our US-licensed specialty wholesale partner and, where applicable, with the manufacturer's global access programme, under DSCSA chain-of-custody.
5. Cold-chain shipment. Zolgensma ships with validated ultra-cold-chain logistics to the administering hospital pharmacy timed to the scheduled infusion date.
6. Infusion and monitoring. The gene-therapy centre administers the one-time IV infusion with peri-infusion corticosteroids, hepatic monitoring, cardiac surveillance, and structured follow-up.

What documentation your physician needs

• Clinical rationale letter confirming SMA diagnosis, SMN1 biallelic status, age and weight, anti-AAV9 serology, hepatic and cardiac baseline, and Zolgensma as the indicated treatment
• Verification of Egyptian Medical Syndicate registration
• SMN1 molecular-testing report and anti-AAV9 antibody titre
• Baseline hepatic panel, cardiac assessment, and weight documentation
• Identification of the gene-therapy-qualified administering centre
• Peri-infusion corticosteroid and monitoring plan

Reserve Meds provides a coordination kit that bundles the EDA and administering-centre templates reviewers expect to see for paediatric gene-therapy named-patient files.

Costs and timing

Zolgensma's US list price for the one-time product sits in an indicative 2026 range of roughly USD 2.1–2.5 million. Total cost of care — including the administering centre's infusion, monitoring, and supportive care — adds incremental local-facility cost. International logistics (ultra-cold chain), EDA documentation handling, importer-of-record fees, and concierge coordination add further cost. Reserve Meds issues a transparent quote at the start of intake, reflecting that Zolgensma is a one-time therapy rather than a recurring-dose product. These figures are indicative, not guaranteed.

Indicative timing — not guaranteed — from intake to infusion is typically 8–14 weeks, driven by serology, centre scheduling, and cold-chain logistics alignment.

Reserve Meds is in pre-launch. Fulfillment availability is limited to our first cohort, and all timelines published on this site are indicative. If your clinical situation is time-sensitive, flag that when you join the waitlist — we triage accordingly. Paediatric SMA cases with narrow age-window eligibility are routinely triaged as urgent.

A culturally-aware note: SMA prevalence in Egypt is elevated by consanguinity, and a growing SMA patient registry means families often connect through patient-support organisations before encountering the named-patient pathway. Our documentation flow is designed to work alongside those community networks.

Reserve Meds's role

• Sourcing. Through our US-licensed specialty wholesale partner and manufacturer access-programme coordination under DSCSA chain-of-custody.
• Documentation. Regulatory package for your physician and EDA review, keyed to the paediatric gene-therapy rationale.
• Logistics. Validated ultra-cold-chain shipment timed to the infusion schedule, plus family travel coordination for cross-border patterns.
• Concierge case lead. A named point of contact for the family through pre-infusion workup, the infusion day, and structured follow-up.

What we do not do: we are not the prescriber, we do not practise medicine, we do not manufacture the gene-therapy product, and we are not the administering centre. All clinical decisions remain with your paediatric neurologist and the gene-therapy centre. We operate on a waitlist basis during our pre-launch phase.

Frequently asked

Can the infusion happen in Egypt? Where a centre has the gene-therapy infrastructure and a path through the manufacturer's qualification process, yes. Otherwise, cross-border referral is the alternative.

My child has had Spinraza — are they still eligible? Prior nusinersen is not a contraindication. Your neurologist decides sequencing.

What if the anti-AAV9 titre is elevated? Current labelling excludes eligibility; your team will discuss Spinraza or Evrysdi alternatives.

Will insurance or philanthropy cover this? Cash-pay is the default for named-patient imports. Philanthropic SMA funds and family fundraising have supported Egyptian Zolgensma cases; we supply documentation but do not manage funding directly.

Next step — join the first-cohort waitlist

Reserve Meds is opening to a limited first cohort in 2026 for gene-therapy coordination. Add your case to the waitlist and our concierge case lead will reach out when we enter intake for Zolgensma coordination.

Add me to the Zolgensma waitlist

> Examples and timings above are composite illustrations drawn from published sources and typical named-patient patterns. Your individual case is assessed by your physician and our clinical-regulatory team; Reserve Meds does not guarantee outcomes or timelines.

---

Reserve Meds is a US-based concierge coordinator for cross-border specialty medicine. We are in pre-launch; service availability is limited to our first cohort and published timelines are indicative, not guarantees. Cash-pay. Export-only (US → overseas). Composite case examples. Not medical advice.

Clinical & regulatory review: Reserve Meds clinical team and AI regulatory-counsel review pipeline. Last medically reviewed: 2026-04-23.